Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ:NMRA)

0.9402 +0.0385 (+4.27%)
Streaming Delayed Price Updated: 9:36 AM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 86,174
Open 0.9000
Bid (Size) 0.9402 (100)
Ask (Size) 0.9496 (1)
Prev. Close 0.9017
Today's Range 0.9000 - 0.9496
52wk Range 0.6110 - 17.19
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill

Performance

YTD
-52.3%
-52.3%
1 Month
-13.7%
-13.7%
3 Month
+29.9%
+29.9%
6 Month
-63.6%
-63.6%
1 Year
-90.9%
-90.9%

More News

Read More
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For May 12, 2025
Via Benzinga
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
From Neumora Therapeutics, Inc.
Via GlobeNewswire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Final NMRA Deadline Reminder: April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via TheNewswire.com
Topics Lawsuit
Final NMRA Deadline Reminder: April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via NewMediaWire
Topics Lawsuit
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRA
From Faruqi & Faruqi LLP
Via GlobeNewswire
NMRA Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit
Via NewMediaWire
Topics Lawsuit
NMRA Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit
Via TheNewswire.com
Topics Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA
From Pomerantz LLP
Via GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
NMRA DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
NMRA DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit
Via TheNewswire.com
Topics Fraud Lawsuit
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Neumora Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
NMRA DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA
From The Rosen Law Firm PA
Via GlobeNewswire
Neumora Therapeutics, Inc. (NMRA) Investors: April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via NewMediaWire
Topics Lawsuit
Neumora Therapeutics, Inc. (NMRA) Investors: April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via TheNewswire.com
Topics Lawsuit
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA
From Pomerantz LLP
Via GlobeNewswire
Neumora Therapeutics, Inc. (NMRA) Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds NMRA Investors of Securities Fraud Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
Neumora Therapeutics, Inc. (NMRA) Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds NMRA Investors of Securities Fraud Class Action Lawsuit
Via TheNewswire.com
Topics Fraud Lawsuit
NMRA Deadline: Rosen Law Firm Urges Neumora Therapeutics, Inc. (NASDAQ: NMRA) Stockholders with Losses to Contact the Firm for Information About Their Rights in Securities Class Action First Filed by the Firm
From The Rosen Law Firm, P.A.
Via Business Wire

Frequently Asked Questions

Is Neumora Therapeutics, Inc. - Common Stock publicly traded?
Yes, Neumora Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Neumora Therapeutics, Inc. - Common Stock trade on?
Neumora Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neumora Therapeutics, Inc. - Common Stock?
The ticker symbol for Neumora Therapeutics, Inc. - Common Stock is NMRA on the Nasdaq Stock Market
What is the current price of Neumora Therapeutics, Inc. - Common Stock?
The current price of Neumora Therapeutics, Inc. - Common Stock is 0.9402
When was Neumora Therapeutics, Inc. - Common Stock last traded?
The last trade of Neumora Therapeutics, Inc. - Common Stock was at 07/09/25 09:36 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.